<?xml version="1.0" ?>
<GlossaryTerm id="CDR0000428262">
  <TermName>tumor vasculature–targeted tumor necrosis factor alpha</TermName>
  <TermPronunciation>(TOO-mer VAS-kyoo-luh-cher-TAR-geh-ted TOO-mer neh-KROH-sis FAK-ter AL-fuh)</TermPronunciation>
  <TermDefinition>
    <DefinitionText>A substance being studied in the treatment of cancer. It is made by linking tumor necrosis factor (TNF) to a peptide. The peptide binds to tumor blood vessels, and TNF damages them. It is a type of biological response modifier. Also called NGR-TNF.</DefinitionText>
    <Dictionary>Cancer.gov</Dictionary>
    <Audience>Patient</Audience>
  </TermDefinition>
  <MediaLink ref="CDR0000713303" type="audio/mpeg" alt="Pronunciation of dictionary term &quot;tumor vasculature–targeted tumor necrosis factor alpha&quot;" language="en" id="_3"/>
  <MediaLink ref="CDR0000713302" type="audio/mpeg" alt="Pronunciation of dictionary term &quot;factor de necrosis tumoral alfa dirigido a la vasculatura tumoral&quot;" language="es" id="_4"/>
  <SpanishTermName>factor de necrosis tumoral alfa dirigido a la vasculatura tumoral</SpanishTermName>
  <SpanishTermDefinition>
    <DefinitionText>Sustancia en estudio para el tratamiento de cáncer. Se elabora al enlazar el factor de necrosis tumoral (FNT) con un péptido. El péptido se une a los vasos sanguíneos del tumor y el FNT los daña. Es un tipo de modificador de la respuesta biológica. También se llama NGR-TNF.</DefinitionText>
    <Dictionary>Cancer.gov</Dictionary>
    <Audience>Patient</Audience>
  </SpanishTermDefinition>
  <DateFirstPublished>2005-05-23</DateFirstPublished>
  <DateLastModified>2008-11-14</DateLastModified>
</GlossaryTerm>
